Preliminary experience with a new institutional tumor board dedicated to patients with neuroendocrine neoplasms.

NEN-TB relies heavily on image review, can impact significant treatment changes in patients with rare tumors like NENs, and was not affected by the switch to a virtual format. Finally, none of the examined factors were predictive of the tumor board recommendations.